Specifications
MLN2238 is a proteasome inhibitor. Much like Bortezomib, MLN2238 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.
Info
| Purity | >99% (HPLC), NMR (conforms) |
| Quantity | 5 mg |
| Molecular Weight | 361.03 Da |
| Physical State | Lyophilized powder |
| Solubility | DMSO (72 mg/mL); ethanol (9 mg/mL) |
| CAS No. | 1072833-77-2 |
| Storage | 4°C, (-20°C Long term). The product can be shipped at room temperature. |
Reviews
There are no reviews yet.